Biocytogen Enters into Antibody Evaluation Option and Licens

Biocytogen Pharmaceuticals a global biotech company focusing on the discovery of novel antibody therapeutics today announces an antibody evaluation option and license agreement with Myricx Bio a UK biotech company focusing on the discovery and development of a completely novel class of selective cytotoxic payloads for antibody drug conjugates ADCs.

Related Keywords

London , City Of , United Kingdom , Beijing , China , United States , Shanghai , San Francisco , California , Yuelei Shen , Robin Carr , Myricx Bio , Haimen Jiangsu , Integrum Renmice , Biocytogen Pharmaceuticals Beijing Co Ltd , Myricx Pharma , Francis Crick Institute , Imperial College London , Linkedin , Project Integrum , Sofinnova Partners , Brandon Capital , Media Contact , Biocytogen Pharmaceuticals Biotech Company Antibody Therapeutics Myricx Bio Drug Conjugates Adcs Cytotoxic Payloads Renmice Dr Yuelei Shen Nmti Robin Carr Renmab Renlite Rennano ,